What it is
Capital Cell is an equity crowdfunding platform from Barcelona that invests only in young biotech, medical-device, diagnostics and digital-health companies. It has been running since 2015 and is run by PFP Capital Cell, S.L. Investors have put €85 million directly into 149 companies through it, and €168 million together with the professional investors who invest alongside them, across 175 funding rounds (October 2026). The site is available in seven languages.
How it works
You choose companies yourself, usually from €500 per round. Each company is first reviewed by the platform's independent network of more than 3,500 scientists, doctors, consultants and lawyers, then by an internal committee, with outside checks of its finances and patents. A professional lead investor, found by the company, sets the price and terms of each round, and the crowd invests alongside. The home page says only 3% of companies that approach the platform are selected; its FAQ says about one applicant in ten. Your money stays with an authorised financial institution until the round completes and is returned if the round fails. You can withdraw within 7 days of committing.
Returns
Capital Cell publishes no yearly return. Its home page shows a portfolio value of 2.7 times the money invested (October 2026), a value on paper based on later funding rounds, not money paid out; the page gives no date or method. It was 3.19 times in November 2022. Very little cash has come back: by November 2022 investors had received about 0.51 euros in cash for every euro invested, from four cash exits, and no newer cash figure has been published. The exits it names are Vytrus, which listed on the stock market, and GoodGut, sold to the drug company HIPRA in 2021; the amounts investors received are not published. Expect to wait: the platform speaks of three to six years, while investors in Bionure, funded in 2017, are still waiting for a return.
Losses and defaults
The platform labels every past round as "in business", "exit" or "write-off". Of the 88 rounds old enough to judge (April 2016 to September 2023), 13 rounds in 12 companies are written off and worth nothing. That is 14.8% of mature rounds, and €7.4 million, about 9% of the roughly €82 million invested directly by August 2026, calculated from the platform's own figures. The platform says 89% of its 149 companies are "in business" (undated, without saying how it counts exits). These figures will rise as younger rounds age, and they leave out companies that are still alive but worth less than investors paid. When a startup fails, shareholders are paid last and usually get nothing back.
What secures your money
Nothing secures your money. You buy a stake in a young company, with no collateral, buyback, reserve fund, insurance or compensation scheme. Usually you do not hold the shares in your own name: a Dutch foundation (a STAK) owns them and issues you certificates that carry your economic and voting rights. The foundation is run by a board of three directors, one of them appointed by Capital Cell. Before a round completes, your money is held by an authorised financial institution, not by the platform or the company. The expert reviews check the science, the patents and the price of one round; they do not protect the value of your shares. Companies often raise more money later, which shrinks earlier investors' share.
Who runs it and its licence
PFP Capital Cell, S.L. (Barcelona) is authorised by Spain's markets regulator, the CNMV, as a crowdfunding service provider under the EU crowdfunding regulation (register no. 12, effective 10 November 2023), and may serve investors in 26 other European countries. Its sole administrator is founder Daniel Oliver. It publishes audited accounts. In 2026 investors in one portfolio company, Bionure (now Accure Therapeutics), reported that their requests for a shareholders' meeting went unanswered and turned to formal legal demands.
Fees
The platform lists no fee for investing; card fees and legal costs are paid by the company raising money. Companies pay an 8% commission on the amount raised plus a €1,500 publication fee. If you sell your certificates to another investor before an exit, Capital Cell charges 8% of the transaction. Check each round's documents for any share of profit taken on a sale, which the platform's FAQ does not list.
Getting your money out
Usually you cannot sell when you want to. There is no maturity date and no repayment promise. Money comes back only if the company is sold, lists on a stock market or buys shares back. The platform runs a noticeboard where sellers can contact buyers, but you must find the buyer yourself, first offer the shares to the company and its founders, and pay 8%. The platform itself calls these investments medium term and without liquidity.
Our view
Return: High — the portfolio is valued at 2.7 times the money invested on paper (October 2026), though only about 0.51 euros per euro had come back as cash by November 2022. Risk: Very High (higher means more risk) — 13 of 88 mature rounds are written off, the cash figure is four years old beside an undated paper value, and some investors report being left without information. Risk-return: Medium — startup shares are high risk and high return by nature, and Capital Cell is the only platform we rate where an independent network of experts reviews every company before it is offered.
PFP Capital Cell, S.L. is authorised by the Spanish Comisión Nacional del Mercado de Valores (CNMV) as a crowdfunding service provider under Regulation (EU) 2020/1503, register no. 12, effective 10 November 2023, with a passport to 26 EEA countries. No deposit guarantee or investor compensation scheme covers investment losses.